FindTrial
Sign In

THERAPEUTIC ALTERNATIVES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

THERAPEUTIC ALTERNATIVES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-003-02
Enrollment
100
Registered
2002-01-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

GROUP C Type of group
Group C: Patients not responding or who relapsed to induction therapy of Interferon alfa 5 MU for 2 weeks followed by combination therapy (randomly selected). C1: Interferon alfa-2b 10 MU subcutaneously daily for 4 weeks associated with ribavirin (induction period). From day 15, the dose of Interferon AIfa-2b will be reduced to 3 MU SC three times a week x 20 weeks and ribavirin will be continued at a dose of 1000 mg / day (patients 75 Kg). The dose of ribavirin is administered in two doses
Group B (Non-responders or patients who relapsed to combination therapy (randomly selected): B1: Interferon alfa-2b 10 MU subcutaneously daily for 2 weeks associated with ribavirin (induction period). From day 15, the dose of Interferon Alfa-2b will be reduced to 3 MU SC three times a week x 22 weeks and ribavirin will be continued at a dose of 1000 mg / day (patients 75 Kg). B2: Interferon alfa-2b 10 MU subcutaneously daily for 4 weeks associated with ribavirin (induction period). From d

Sponsors

SCHERING PLOUGH RESEARCH INSTITUTE,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients with chronic hepatitis C. 2) Anti-HCV positive by enzyme immunoassay (ELIZA) of second generation or recombinant Immunoblot (RIBA).

Exclusion criteria

Exclusion criteria: Any other etiology of liver disease, based on clinical history and biopsy (if necessary), other than chronic hepatitis C.

Countries

Peru

Contacts

Public ContactOscar Barrenechea

SCHERING PLOUGH DEL PERU S.A.

oscar.barrenechea@spcorp.com710-3661

Outcome results

None listed

Source: REPEC (via WHO ICTRP)